Case Profile of Anemia Associated with Myelodysplastic Syndrome (MDS) Treated with Darbepoetin alfa - Dr. Rishu Vidhatri
This case discusses a 62-year-old male diagnosed with Myelodysplastic Syndrome (MDS) presenting with severe anemia and transfusion dependence. Despite regular transfusions, the patient continued to experience fatigue and dyspnea, significantly impacting quality of life.
With a serum erythropoietin level <750 mIU/mL, treatment with darbepoetin alfa was initiated, leading to a clinically meaningful hemoglobin rise from 5.6 g/dL to 9 g/dL and notable symptomatic improvement.
This case highlights the importance of early ESA therapy, patient selection based on EPO levels, and targeted management in intermediate-risk MDS to reduce transfusion burden and improve outcomes.
Watch to understand:
• When to initiate ESA in MDS
• Role of darbepoetin alfa in anemia management
• Practical insights for improving patient quality of life
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.